Crossmark

Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology

Crossref DOI link: https://doi.org/10.1016/j.aohep.2026.102195

Published Print: 2026-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Zou, Min

Yang, Shiye

Feng, Jinkai

Yang, Zengqiang
License Information

Text and Data Mining valid from 2026-01-01

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2026-02-10
More Information

This article is maintained by: Elsevier

Article Title: Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology

Journal Title: Annals of Hepatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.aohep.2026.102195

Content Type: simple-article

Copyright: © 2026 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below